# Biorestorative Therapies Inc. (BRTX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3M  
**Price:** $0.38 (-3.65%)

> BioRestorative Therapies Inc. is a regenerative medicine company developing advanced stem cell-based therapies and products. The company operates three primary business segments: its disc and spine program featuring BRTX-100, an autologous mesenchymal stem cell therapy designed to treat chronic lower back and neck pain from degenerative disc disease; its metabolic program called ThermoStem®, which utilizes brown adipose-derived stem cells to address obesity and metabolic disorders; and a commercial BioCosmeceutical platform offering cell-based secretome products containing exosomes, proteins, and growth factors engineered for aesthetic applications to reduce fine lines and wrinkles. BRTX-100 is currently in Phase 2 clinical trials and has received FDA Fast Track designation for chronic lumbar disc disease treatment. The company's approach leverages proprietary cell and tissue protocols using primarily adult stem cells collected from patients' own bone marrow or derived from other tissue sources. Founded by scientists and researchers focused on addressing unmet medical needs, BioRestorative combines clinical development with commercial product offerings in the emerging field of cell-based therapeutics and aesthetic medicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $359,700 | $335,856 | -$16M | -$14M | — |
| 2024 | $401,000 | $372,928 | -$12M | -$9M | — |
| 2023 | $145,800 | $145,800 | -$15M | -$10M | — |
| 2022 | $119,800 | — | -$19M | -$13M | — |
| 2021 | $46,000 | — | -$26M | -$44M | — |
| 2020 | $77,000 | — | -$3M | -$11M | — |
| 2019 | $130,000 | — | -$8M | -$15M | — |
| 2018 | $111,000 | — | -$8M | -$13M | — |
| 2017 | $81,000 | $81,000 | -$8M | -$9M | — |
| 2016 | $36,355 | $36,253 | -$8M | -$9M | — |
| 2015 | $628,915 | $367,411 | -$7M | -$8M | — |
| 2014 | $415,996 | $202,162 | -$5M | -$6M | — |
| 2013 | $1,680 | $1,472 | -$5M | -$6M | — |
| 2012 | $15,589 | $14,282 | -$6M | -$7M | — |
| 2011 | — | — | -$4M | -$4M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4M | $4M | $356,744 | $2M | — |
| 2024 | $12M | $4M | $9M | $547,890 | — |
| 2023 | $13M | $3M | $10M | $884,377 | — |
| 2022 | $16M | $6M | $10M | $2M | — |
| 2021 | $22M | $856,497 | $11M | $21M | $250,000 |
| 2020 | $4M | $6M | -$1M | — | — |
| 2019 | $1M | $14M | -$13M | — | — |
| 2018 | $1M | $10M | -$9M | — | — |
| 2017 | $2M | $9M | -$7M | — | — |
| 2016 | $2M | $7M | -$5M | — | — |
| 2015 | $2M | $6M | -$4M | — | — |
| 2014 | $2M | $9M | -$7M | — | — |
| 2013 | $1M | $8M | -$7M | — | — |
| 2012 | $1M | $6M | -$5M | — | — |
| 2011 | $220,973 | $4M | -$4M | — | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$11M | $116,069 | -$11M |
| 2024 | -$8M | $106,189 | -$8M |
| 2023 | -$6M | $171,043 | -$7M |
| 2022 | -$6M | $265,223 | -$6M |
| 2021 | -$3M | $30,658 | -$3M |
| 2020 | -$2M | — | — |
| 2019 | -$7M | $35,631 | -$7M |
| 2018 | -$5M | $12,869 | -$5M |
| 2017 | -$4M | $3,617 | -$4M |
| 2013 | -$3M | $11,160 | -$3M |
| 2012 | -$3M | $2,533 | -$3M |
| 2011 | -$3M | $17,772 | -$3M |
| 2010 | -$729,218 | $45,383 | -$774,601 |

Source: [CompaniesByCap](https://companiesbycap.com/company/BRTX)